The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Intermittent androgen-deprivation therapy in the management of castrate-resistant prostate cancer (CRPCa): Results of a multi-institutional randomized prospective clinical trial.
Michael Organ
No relevant relationships to disclose
Lori Wood
No relevant relationships to disclose
Derek Wilke
No relevant relationships to disclose
Chris Skedgel
No relevant relationships to disclose
Kara Thompson
No relevant relationships to disclose
Scott North
No relevant relationships to disclose
Tina Cheng
No relevant relationships to disclose
Susan Winch
No relevant relationships to disclose
Ricardo Rendon
No relevant relationships to disclose